Long noncoding RNA CCAT2 can predict metastasis and a poor prognosis: A meta-analysis

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Colon cancer associated transcript 2 (CCAT2) is a novel long non-coding RNA (lncRNA) implicated in tumorigenesis.
• Understanding the role of CCAT2 in various cancers is crucial for developing new diagnostic and prognostic tools.

Purpose of the Study:

• To systematically evaluate the association between CCAT2 expression and clinical outcomes in human cancers through a meta-analysis.
• To determine if CCAT2 can serve as a predictive biomarker for cancer progression and survival.

Main Methods:

• A comprehensive literature search was performed across multiple databases (PubMed, Cochrane, CNKI, Wan Fang).
• Data from 9 eligible studies were analyzed using Odds Ratios (ORs) and Hazard Ratios (HRs) with 95% Confidence Intervals (CIs).
• Statistical analyses were conducted using Revman5.3 and Stata12.0 software.

Main Results:

• Elevated CCAT2 expression was significantly associated with increased risk of distant metastasis (OR=12.42) and lymph node metastasis (OR=3.60).
• High CCAT2 expression correlated with poorer overall survival (HR=1.53) and progression-free survival (HR=2.88).

Conclusions:

• CCAT2 expression levels are significantly correlated with adverse clinical outcomes in human cancers.
• CCAT2 shows potential as a novel biomarker for predicting patient prognosis and guiding clinical management.